European drug regulator OKs Novartis’ meningitis B vaccine, 1st shot to protect against strain

LONDON – Europe’s top drug regulator has recommended approval for the first vaccine against meningitis B, made by Novartis AG.

There are five types of bacterial meningitis. While vaccines exist to protect against the other four, none has previously been licensed for type B meningitis. In Europe, type B is the most common, causing several thousand cases every year.

Meningitis mainly affects infants and children. It kills about 8 per cent of patients and leaves others with lifelong consequences, like brain damage.

In a statement on Friday, Andrin Oswald of Novartis said he was “proud of the major advance” the company had made in developing its vaccine Bexsero.

Recommendations from the European Medicines Agency are usually adopted by the European Commission. Novartis is also seeking to test the vaccine in the U.S.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.